Abstract
Three subtypes of small bowel neuroendocrine tumours (SBNETs) have been described: Type A: SBNET with resectable mesenteric disease that does not involve the mesenteric root; Type B: “Borderline resectable” SBNET presenting with mesenteric nodal metastases and fibrosis adjacent but not encasing the main trunk of the superior mesenteric artery (SMA) and superior mesenteric vein (SMV); and Type C: “Locally advanced or irresectable” SBNET where tumour deposits and fibrosis encase the SMA and SMV. Type C SBNETs are rare and constitute around 5% of patients in reported series, although this may underestimate the prevalence. In these patients, almost all will present with symptoms of intestinal ischemia or obstruction and symptom management should be a primary main focus of treatment. All patients should be carefully staged with cross-sectional imaging and 68 Ga-dotate positron emission tomography, and discussed at a dedicated neuroendocrine tumour multidisciplinary meeting. Expert surgical review should always be sought as experienced centers have a high rate of successful resection of primary tumours and mesenteric disease. If resection is not feasible, surgical bypass should be considered in patients with a discrete and symptomatic point of obstruction. Non-operative management should emphasize symptomatic treatment with somatostatin analogs, nutritional advice and support and palliative care. Successful neoadjuvant approaches utilizing peptide radionucleide receptor therapy and systemic chemotherapy with everolimus or temazolamide/capecitabine have not been reported.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342
Chan DL, Dixon M, Law CL et al (2018) Outcomes of cytoreductive surgery for metastatic low-grade neuroendocrine tumors in the setting of extrahepatic metastases. Ann Surg Oncol 25(6):1768–1774
Erikson J, Garmo H, Hellman P et al (2017) The influence of preoperative symptoms on the death of patients with small intestinal neuroendocrine tumours. Ann Surg Oncol 24:1214–1220
Ellis L, Shale MJ, Coleman MP (2010) Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 105:2563–2569
Niederle B, Pape UF, Costa F et al (2016) ENETS consensus guidelines update for neuroendocrine neoplasm of the jejunum and ileum. Neuroendocrinology 103(2):125–138
Laskaratos FM, Diamantopoulos L, Walker M et al (2018) Prognostic factors for survival among patients with small bowel neuroendocrine tumours associated with mesenteric desmoplasia. Neuroendocrinology 1:1–15. https://doi.org/10.1159/00486097
Chambers AJ, Pasieka JL, Dixon E et al (2008) The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 144:645–651 Discussion 651-653
Pasquer A, Walter T, Hervieu V et al (2015) Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol 22(Suppl 3):S742–S749
Watzka FM, Fottner C, Miederer M et al (2016) Surgical treatment of NEN of small bowel: a retrospective analysis. World J Surg 40:749–758. https://doi.org/10.1007/s00268-016-3432-2
Gaujoux S, Sauvanet A, Belghiti J (2012) Place of surgical resection in the treatment strategy for gastrointestinal neuroendocrine tumors. Targ Oncol 7:153–159
Blazevic A, Zandee WT, Franssen GJH et al (2018) Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer 25:245–254
de Mestier L, Lardiere-Deguelte S, Brixi H et al (2015) Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. Neuroendocrinology 101:105–111
Manguso N, Gangi A, Nissen N et al (2018) Long-term outcomes after elective versus emergency surgery for small bowel endocrine tumors. Am Surg 84:1570–1574
Partelli S, Bartsch DK, Capdevila J et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology 105:255–265
Pantongrag-Brown L, Buetow PC, Carr NJ et al (1995) Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. Am J Radiol 164:387–391
Laskaratos F-M, Rombouts K, Caplin M et al (2017) Neuroendocrine tumours and fibrosis: an unsolved mystery. Cancer 123:4770–4790
Cirri P, Cihiarugi P (2012) Cancer-associated-fibroblasts and tumour cells: a diabolic liason driving cancer progression. Cancer Metastasis Rev 31:195–208
Nebigil CG, Launay LM, Hickel P et al (2000) 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci USA 97:2591–2596
Launay JM, Birraux G, Bondoux D et al (1996) Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem 271:3141–3147
Woodard PK, Feldman JM, Paine SS et al (1995) Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 19:400–405
Beauchamp RD, Coffey RJ Jr, Lyons RM et al (1991) Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 51:5253–5260
Cunningham JL, Tsolakis AV, Jacobson A et al (2010) Connective tissue growth factor expression in endocrine tumors is associated with high stromal expression of alpha-smooth muscle actin. Eur J Endocrinol 163:691–697
La Rosa S, Chiaravalli AM, Capella C et al (1997) Immunohistochemical localization of acidic fibroblast growth factor in normal human enterochromaffin cells and related gastrointestinal tumours. Virchows Arch 25:175–180
Pavel M, Valle JW, Eriksson B et al (2017) ENETS consensus guidelines for the standard of care in neuroendocrine neoplasms: Systemic therapy, biotherapy and novel targeted agents. Neuroendocrinology 105(3):266–280
Lee L, Ito T, Jensen RT (2018) Everolimus in treatment of neuroendocrine tumors: efficacy, side effects, resistance and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 19(8):909–928
Ramirez RA, Beyer DT, Chauhan A et al (2016) The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist 21(6):671–675
Hellman P, Hessman O, Akerstrom G, Stalberg P (2010) Stenting of the superior mesenteric vein in midgut carcinoid disease with large mesenteric masses. World J Surg 34(6):1373–1379. https://doi.org/10.1007/s00268-009-0361-3
Acknowledgements
The CommNETS Surgical Section includes Dr Julie Hallett and Dr Calvin Law from the Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Dr Janice Pasieka, Tom Baker Cancer Centre, Alberta, Canada; Dr Jonathan Koea, North Shore Hospital, Auckland, New Zealand; Dr Win Meyer-Rochow, Waikato Hospital, Hamilton, New Zealand.
Funding
The CommNETS Collaboration is supported by unconditional educational grant from Ipsen Canada and an unconditional sponsorship grant from Ipsen Australia.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is contribution to the Symposium entitled, Surgical Dilemmas and Challenges for the Operating Surgeon in the Management of Small Bowel Neuroendocrine Tumours: A CommNETs Symposium.
Rights and permissions
About this article
Cite this article
Koea, J., the Commonwealth Neuroendocrine Tumour Research Collaborative (CommNETs) Surgical Section. Management of Locally Advanced and Unresectable Small Bowel Neuroendocrine Tumours. World J Surg 45, 219–224 (2021). https://doi.org/10.1007/s00268-020-05740-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-020-05740-7